MX367352B - Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. - Google Patents

Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.

Info

Publication number
MX367352B
MX367352B MX2014008180A MX2014008180A MX367352B MX 367352 B MX367352 B MX 367352B MX 2014008180 A MX2014008180 A MX 2014008180A MX 2014008180 A MX2014008180 A MX 2014008180A MX 367352 B MX367352 B MX 367352B
Authority
MX
Mexico
Prior art keywords
methods
patient
cardiovascular disease
reducing risk
ldl
Prior art date
Application number
MX2014008180A
Other languages
English (en)
Other versions
MX2014008180A (es
Inventor
L Bisgaier Charles
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of MX2014008180A publication Critical patent/MX2014008180A/es
Publication of MX367352B publication Critical patent/MX367352B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para reducir los niveles de LDL-C en plasma en un paciente que recibe una dosis estable de estatina donde el paciente tiene un nivel de LDL-C mayor que el objetivo de tratamiento. Métodos para reducir el riesgo de un paciente de desarrollar una enfermedad cardíaca coronaria o de tener un evento cardiovascular recurrente donde el paciente está recibiendo una dosis estable de estatina y el paciente tiene un nivel de LDL-C mayor que el objetivo de tratamiento.
MX2014008180A 2012-01-06 2013-01-04 Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. MX367352B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Publications (2)

Publication Number Publication Date
MX2014008180A MX2014008180A (es) 2014-10-14
MX367352B true MX367352B (es) 2019-08-16

Family

ID=48745439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008180A MX367352B (es) 2012-01-06 2013-01-04 Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.

Country Status (9)

Country Link
US (2) US10028926B2 (es)
EP (2) EP3735967A1 (es)
JP (2) JP6295205B2 (es)
CN (2) CN104136023A (es)
AU (1) AU2013207423B2 (es)
CA (1) CA2861643C (es)
HK (1) HK1201452A1 (es)
MX (1) MX367352B (es)
WO (1) WO2013103842A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3590949T (lt) 2010-10-01 2022-07-25 Modernatx, Inc. Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX354267B (es) 2011-10-03 2018-02-21 Moderna Therapeutics Inc Star Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JP2017533973A (ja) 2014-11-14 2017-11-16 ジェムフィアー セラピューティクス インコーポレイテッド α，ω−ジカルボン酸末端ジアルカンエーテルを調製するためのプロセスおよび中間体
CN114099496A (zh) 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3370713A4 (en) 2015-11-06 2019-10-23 Gemphire Therapeutics Inc. TREATMENT OF MIXED DYSLIPIDEMIA
MX2018010096A (es) * 2016-02-26 2018-11-09 Gemphire Therapeutics Inc Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.
MX2019009418A (es) * 2017-02-08 2019-10-02 Esperion Therapeutics Inc Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CN110996928A (zh) * 2017-04-18 2020-04-10 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法
TW201906599A (zh) * 2017-05-11 2019-02-16 美商珍費爾醫療公司 吉卡賓組成物及其使用方法
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
CN115429784A (zh) 2019-06-21 2022-12-06 艾斯柏伦治疗公司 制备贝派地酸及其组合物的方法
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
DE60037818D1 (de) 1999-04-01 2008-03-06 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
CA2425121A1 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
CN101522623B (zh) * 2006-08-03 2013-06-12 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法

Also Published As

Publication number Publication date
EP2800564A4 (en) 2015-07-22
AU2013207423A1 (en) 2014-07-24
US10028926B2 (en) 2018-07-24
EP2800564B1 (en) 2020-05-06
AU2013207423B2 (en) 2017-10-12
CN104136023A (zh) 2014-11-05
US10709678B2 (en) 2020-07-14
CA2861643C (en) 2020-10-06
MX2014008180A (es) 2014-10-14
WO2013103842A1 (en) 2013-07-11
CN110025608A (zh) 2019-07-19
JP2018104452A (ja) 2018-07-05
JP2015503588A (ja) 2015-02-02
EP3735967A1 (en) 2020-11-11
EP2800564A1 (en) 2014-11-12
HK1201452A1 (en) 2015-09-04
US20180303779A1 (en) 2018-10-25
JP6295205B2 (ja) 2018-03-14
US20150005386A1 (en) 2015-01-01
CA2861643A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
MX367352B (es) Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MX2016000173A (es) Sistemas y metodos para seguimiento y presentacion de datos de terapia para acufenos.
NZ603319A (en) Diabetes therapy
EP3346915A4 (en) Systems, devices, components and methods for detecting the locations of sources of cardiac rhythm disorders in a patient's heart
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2011013739A (es) Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante.
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2013090118A3 (en) Heart rate variability and heart rate variation
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
WO2012093258A3 (en) Irf5- related treatment and screening
EP2513336A4 (en) METHOD FOR CHARACTERIZING THE IMMUNE FUNCTION OF EX VIVO INDUCTIVE HOST OF OFFENSIVE AND DEFENSIVE IMMUNE MARKERS
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
EP2545929A4 (en) ENHANCING OR TREATING AGENT FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND / OR MICTION DISORDERS
MX2014001823A (es) Combinaciones de corroles y estatinas.
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
UA50950U (ru) Способ лечения больных острым коронарным синдромом с учетом генотипа
RU2010100736A (ru) Способ хирургического лечения щитовидной железы
UA107786C2 (ru) Способ оценки эффективности лечения s-амплодипина больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа
UA107787C2 (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа
MX2012013052A (es) Asociacion de inhibidores de la xantina oxidasa y la instantina y su uso.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GEMPHIRE THERAPEUTICS, INC.

FG Grant or registration